A peer-reviewed review in the Journal of Huntington's Disease, published online November 26, 2025, has formally reported the 36-month topline results of uniQure's phase I/II trial of AMT-130, an experimental one-time gene therapy delivered directly into the brain. Writing in the journal's regular Clinical Trials Update, researchers Mena Farag, Sarah Tabrizi and Edward Wild of University College London state that high-dose AMT-130 met the trial's primary endpoint at 36 months, showing a statistically significant 75 percent slowing of disease progression on the composite Unified Huntington's Disease Rating Scale (cUHDRS) compared with an external control group (p = 0.003). A secondary measure, Total Functional Capacity, showed a 60 percent slowing in the same comparison (p = 0.033).
The comparison was not against a concurrent placebo arm. Because AMT-130 requires brain surgery to deliver, the trial has no randomized, blinded control group; instead, outcomes for the 12 high-dose and 12 low-dose patients who had reached the 36-month assessment were compared with propensity-score-matched external controls, 940 and 626 people respectively, drawn from the Enroll-HD natural history registry, an ongoing observational study of people with Huntington's disease. The trial treated 29 people in total across the United States, United Kingdom and European Union. The review also reports that cerebrospinal fluid levels of neurofilament light, a marker of nerve cell damage, were about 8 percent below baseline at 36 months in the high-dose group, and that the therapy was generally well tolerated, with no new drug-related serious adverse events reported since December 2022 and most adverse events tied to the surgical delivery procedure resolving afterward.
The published figures are the same ones this newspaper reported when uniQure said in June 2026 that the FDA had agreed the three-year data could support a Biologics License Application under the accelerated approval pathway, with a filing planned for the third quarter of 2026. What the journal article adds is an independent, peer-reviewed accounting of the trial's design, including the explicit caveat that the comparison relies on statistical matching to an external, non-randomized population rather than a randomized controlled trial run in parallel. UniQure has said any accelerated approval would carry a requirement to run a confirmatory study with a standard-of-care control group.